The head of Moscow’s Gamaleya National Center of Epidemiology and Microbiology, which created the Sputnik V Covid-19 vaccine, and the boss of the fund that bankrolled its development, have spoken to RT about a fresh study that has found the jab to be much more effective against the Omicron variant than the German-American Pfizer formula.
A comparative Italian-Russian paper, published earlier this week, revealed that Sputnik V was 2.6 times better in tackling Omicron than the popular Western alternative.
Sputnik V has shown a more-than-eightfold reduction of virus-neutralizing activity against the new super-mutant coronavirus strain, in contrast to a 21.4-fold drop for the Pfizer vaccine, according to the study by Italy’s Lazzaro Spallanzani National Institute for Infectious Diseases and the aforementioned Gamaleya Center. The paper also said Sputnik Light, a one-shot version of the product, provided significantly increased virus-neutralizing activity against Omicron when used as a booster.